About this Research Topic
Chronic inflammation serves as a distinguishing characteristic of numerous human diseases, encompassing cardiovascular diseases, bone disorders, and so on forth. Recently, immunoregulation strategies that could activate immunity or modulate immune cells were employed to combat chronic inflammation have sparked significant research interest. Thereinto,
immunomodulation through nano/biomaterials gained tremendous attention for inflammation resolving.
Given that chronic inflammation is a central pathological feature throughout all stages of atherosclerosis, immunoregulation strategies such as inhibition of monocyte recruitment, suppression of macrophage proliferation, restoration of efferocytosis, etc., are effective to resolve inflammation while minimizing adverse effects. These approaches might provide desirable therapeutic benefits by implement of immunoregulation to local immune cells, especially monocytes or macrophages. The targeted delivery of nanotherapeutics, cytokines, or drugs to macrophages that could polarize macrophages towards a less-inflammatory, M2-like subtype that promote regression of atherosclerotic plaques, are of considerable interest. In the inflammation-relevant bone diseases, suppressing continuable inflammation progression by immunoregulation is of significance to reinforce impaired tissue regeneration at injured sites. It is well-recognized that the balance between M1 and M2 macrophage polarization is critical in decreasing inflammatory response and accelerating tissue remodeling. Thus, immunoregulation strategies hold promise for precise and controlled modulation of the immune response for inflammation resolving.
The aim of this topic is to discover innovative strategies that can directly initiate immunoregulation to resolve tissue inflammation, in particular the treatment for inflammation-characterized cardiovascular disease and bone inflammation-relevant disorders. This topic is expected to provide a platform for advancing research on the deep understanding the mechanisms of immunotherapy or immunomodulation in the mentioned-above diseases. It is noteworthy that regulation methods of monocytes, macrophages, natural killer cells, T cells, and other engineered immune cells, are particularly interest of this research topic.
This topic provides a reference for the development of strategies for inflammation-relevant disease treatment from immunomodulation perspective. We welcome Original Research, Review articles, and other article types, focusing on the following subtopics, but not limited to:
- Unravelling underlying mechanisms in chronic inflammation-relevant disorders, such as atherosclerosis, myocardial infarction, and inflammatory bone disease.
- Innovative immunoregulation strategies that manipulate immune cells to resolve local or systemic inflammation for the management of inflammatory diseases.
- Application of rationally designed nanoparticles or biomaterials that initiate or induce immune modulation for inhibition of activation of inflammation signaling pathways.
- Modulation of macrophage polarization (M1 or M2 phenotype) in the progression and regression of inflammation-relevant disorders.
- Delivery of immunomodulatory therapeutics, agents, RNA (mRNA, miRNA, siRNA, e.g.,) cytokines, specialized pro-resolving mediators (SPMs) for resolution of inflammation.
Note: please be noted that manuscripts without a major focus or immunological mechanisms are out of scope for this journal.
immunomodulation through nano/biomaterials gained tremendous attention for inflammation resolving.
Given that chronic inflammation is a central pathological feature throughout all stages of atherosclerosis, immunoregulation strategies such as inhibition of monocyte recruitment, suppression of macrophage proliferation, restoration of efferocytosis, etc., are effective to resolve inflammation while minimizing adverse effects. These approaches might provide desirable therapeutic benefits by implement of immunoregulation to local immune cells, especially monocytes or macrophages. The targeted delivery of nanotherapeutics, cytokines, or drugs to macrophages that could polarize macrophages towards a less-inflammatory, M2-like subtype that promote regression of atherosclerotic plaques, are of considerable interest. In the inflammation-relevant bone diseases, suppressing continuable inflammation progression by immunoregulation is of significance to reinforce impaired tissue regeneration at injured sites. It is well-recognized that the balance between M1 and M2 macrophage polarization is critical in decreasing inflammatory response and accelerating tissue remodeling. Thus, immunoregulation strategies hold promise for precise and controlled modulation of the immune response for inflammation resolving.
The aim of this topic is to discover innovative strategies that can directly initiate immunoregulation to resolve tissue inflammation, in particular the treatment for inflammation-characterized cardiovascular disease and bone inflammation-relevant disorders. This topic is expected to provide a platform for advancing research on the deep understanding the mechanisms of immunotherapy or immunomodulation in the mentioned-above diseases. It is noteworthy that regulation methods of monocytes, macrophages, natural killer cells, T cells, and other engineered immune cells, are particularly interest of this research topic.
This topic provides a reference for the development of strategies for inflammation-relevant disease treatment from immunomodulation perspective. We welcome Original Research, Review articles, and other article types, focusing on the following subtopics, but not limited to:
- Unravelling underlying mechanisms in chronic inflammation-relevant disorders, such as atherosclerosis, myocardial infarction, and inflammatory bone disease.
- Innovative immunoregulation strategies that manipulate immune cells to resolve local or systemic inflammation for the management of inflammatory diseases.
- Application of rationally designed nanoparticles or biomaterials that initiate or induce immune modulation for inhibition of activation of inflammation signaling pathways.
- Modulation of macrophage polarization (M1 or M2 phenotype) in the progression and regression of inflammation-relevant disorders.
- Delivery of immunomodulatory therapeutics, agents, RNA (mRNA, miRNA, siRNA, e.g.,) cytokines, specialized pro-resolving mediators (SPMs) for resolution of inflammation.
Note: please be noted that manuscripts without a major focus or immunological mechanisms are out of scope for this journal.
Keywords: biomaterials, immune response activation, chronic inflammation, immunoregulation strategy
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
